Skip to main content
SpringerLink
Log in

Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background: The Acne-Specific Quality of Life Questionnaire (Acne-QoL) is a responsive, reliable and valid instrument developed to measure the impact of facial acne across four dimensions of patient QOL. Score changes on this instrument have been used to report statistically significant treatment advantages for a low-dose oral contraceptive (Estrostep®), containing norethisterone (norethindrone) acetate (NA) 1mg and ethinylestradiol (EE) [20, 30, 35mg] as compared with placebo in women with moderate acne vulgaris. However, the question remained if these statistically significant results were also clinically meaningful.

Objectives: To evaluate the statistically significant Acne-QoL benefits observed with NA/EE in terms of their clinical significance, and to compare the three different approaches for defining a minimal clinically important difference (MCID) for the Acne-QoL instrument.

Methods: Since the optimum method for estimating MCIDs has yet to be established, three different published approaches for determining MCIDs were applied and compared using data from two randomised, double-blind, placebocontrolled studies of the efficacy of NA/EE in the treatment of facial acne.

Results: Although the approaches differed substantially, the resulting MCID estimates were comparable. Specifically, the MCID estimates ranged from 0.50–10.3 mean change per item, depending on the domain. The results showed that the statistically significant treatment advantages for NA/EE were also clinically significant.

Conclusion: When applied to the change scores present, the results showed that the statistically significant treatment advantages for NA/EE were also clinically significant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Fig. 1
Table VII

Similar content being viewed by others

Notes

  1. The use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Layton AM. Psychological aspects of acne vulgaris. J Cutan Med Surg 1998; 2: 19–23

    PubMed  Google Scholar 

  2. Jaeschke R, Singer J, Guyatt G. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407–15

    Article  PubMed  CAS  Google Scholar 

  3. Maloney JM, Arbil DI, Flack M, et al. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Womens Health 2001; 1: 123–31

    Article  CAS  Google Scholar 

  4. Girman CJ, Hartmaier S, Thiboutout D, et al. Evaluating healthrelated quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Qual Life Res 1996; 5: 481–90

    Article  PubMed  CAS  Google Scholar 

  5. Martin AR, Lookingbill DP, Botek A, et al. Health-related quality of life among patients with facial acne: assessment of a new acne-specific questionnaire. Clin Exp Dermatol 2001 Jul; 26 (5): 380–5

    Article  PubMed  CAS  Google Scholar 

  6. Fehnel SE, McLeod LD, Brandman J, et al. Responsiveness of the Acne-Specific Quality of Life Questionnaire (Acne-QoL) to treatment for acne vulgaris in placebo-controlled clinical trials. Qual Life Res 2002 Dec; 11 (8): 809–16

    Article  PubMed  CAS  Google Scholar 

  7. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: 81–7

    Article  PubMed  CAS  Google Scholar 

  8. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health related quality of life scores. J Clin Oncol 1998; 16: 139–44

    PubMed  CAS  Google Scholar 

  9. Jones PW and the Nedocromil Sodium Quality of Life Study Group. Quality of life, symptoms and pulmonary function in asthma: long term treatment with nedocromil sodium examined in a controlled multicentre trail. Eur Respir J 1994; 7: 55–62

    Article  PubMed  CAS  Google Scholar 

  10. Norman GR, Sridhar FG, Guyatt GH, et al. Relation of distribu-tion- and anchor-based approaches in interpretation of changes in health related quality of life. Med Care 2001; 39: 1039–47

    Article  PubMed  CAS  Google Scholar 

  11. Guyatt GH, Juniper EF, Walter SD, et al. Interpreting treatment effects in randomized trails. BMJ 1998; 316: 690–2

    Article  PubMed  CAS  Google Scholar 

  12. Cohen J. Statistical power: analysis for the behavioral sciences. New York: Academic Press, 1977

    Google Scholar 

Download references

Acknowledgements

This study was solely funded by Pfizer, Inc., manufacturers of Estrostep®.

Author information

Authors and Affiliations

  1. RTI Health Solutions, Research Triangle Institute, 3040 Cornwallis Rd, PO Box 12194, Research Triangle Park, North Carolina, 27709-2194, USA

    Lori D. McLeod & Sheri E. Fehnel

  2. Pfizer Pharmaceutical Group, New York, USA

    Jane Brandman

  3. Pfizer Global Research and Development, Sandwich, UK

    Tara Symonds

Authors
  1. Lori D. McLeod
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheri E. Fehnel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jane Brandman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tara Symonds
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lori D. McLeod.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McLeod, L.D., Fehnel, S.E., Brandman, J. et al. Evaluating minimal clinically important differences for the acne-specific quality of life questionnaire. Pharmacoeconomic 21, 1069–1079 (2003). https://doi.org/10.2165/00019053-200321150-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200321150-00001

Keywords

Search

Navigation